Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel
Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) said it treated the first recurrent glioblastoma patient in Israel and the first outside the U.S. with its Alpha DaRT® system at Hadassah University Medical Center in Jerusalem. The company said the minimally invasive stereotactic procedure used a brain applicator and was completed without unexpected complications under the ALL protocol.
How this was made
The 30-second read
Why it matters
The announcement is a concrete clinical execution milestone: the first recurrent GBM patient treated with Alpha DaRT in Israel and the first outside the U.S., under the ALL broad-access protocol at Hadassah.
Market read
Investors get a new, first-in-geography clinical milestone for Alpha DaRT in recurrent glioblastoma, supporting execution credibility but not yet providing efficacy endpoints.
What to watch
The release emphasizes feasibility and absence of unexpected complications but provides no quantitative clinical outcomes; watch for subsequent patient follow-up, enrollment pace, and any protocol deviations or regulatory/operational updates.
Background
Alpha Tau’s Alpha DaRT is an intratumoral alpha-radiation therapy using radium-224 sources delivered via a stereotactic burr-hole system; glioblastoma recurrence has no established standard of care.
Ticker impact
Alpha Tau reports the first recurrent glioblastoma patient treated with Alpha DaRT outside the U.S., in Israel at Hadassah.
Near-term sentiment tailwind; magnitude likely limited until additional efficacy/safety readouts or trial enrollment updates are disclosed.
The release is a concrete clinical execution update (first Israel/first outside U.S.) with no new efficacy datapoint, but it reinforces ongoing REGAIN trial momentum and FDA clearance context mentioned in the text.
Market effects
Adds a proof-of-technical-feasibility datapoint for alpha-radiation intratumoral delivery in intracranial oncology, potentially supportive for the broader radiopharmaceutical/oncology delivery narrative.
Highlights Israel as an active clinical site for advanced neuro-oncology device/therapy delivery, which can improve perceived global trial scalability.
First outside-U.S. treatment can broaden investor perception of international commercialization/trial expansion potential, though clinical outcomes remain pending.
Counterpoint
A single successfully treated patient is not evidence of efficacy; investors may overestimate impact until survival/response data or safety signals are reported.
Key entities
- companyAlpha Tau Medical Ltd.
Developer of Alpha DaRT alpha-radiation cancer therapy; Nasdaq-listed as DRTS/DRTSW.
- technologyAlpha DaRT®
Diffusing Alpha-emitters Radiation Therapy using radium-224 impregnated sources delivered stereotactically for intracranial tumors.
- institutionHadassah University Medical Center
Jerusalem medical center where the first Israel/outside-U.S. recurrent GBM patient was treated.
- clinical_programALL protocol
Broad-access clinical protocol at Hadassah for solid tumors amenable to Alpha DaRT source delivery.
- clinical_programREGAIN trial
Multicenter U.S. recurrent GBM trial referenced as continuing recruitment after interim results and FDA clearance to full enrollment.
